MERSANA THERAPEUTICS INC's ticker is MRSN and the CUSIP is 59045L106. A total of 113 filers reported holding MERSANA THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.35 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $111 | -71.8% | 87,113 | -27.0% | 0.00% | – |
Q2 2023 | $394 | -21.2% | 119,345 | -1.7% | 0.00% | – |
Q1 2023 | $500 | -29.3% | 121,377 | +0.7% | 0.00% | – |
Q4 2022 | $707 | -99.9% | 120,519 | +7.6% | 0.00% | – |
Q3 2022 | $758,000 | +17.3% | 112,039 | -19.9% | 0.00% | – |
Q2 2022 | $646,000 | +17.2% | 139,819 | +1.3% | 0.00% | – |
Q1 2022 | $551,000 | -22.6% | 138,034 | +20.6% | 0.00% | – |
Q4 2021 | $712,000 | -92.3% | 114,447 | -88.3% | 0.00% | -100.0% |
Q3 2021 | $9,250,000 | -70.6% | 980,896 | -57.7% | 0.00% | -66.7% |
Q2 2021 | $31,475,000 | -34.6% | 2,317,747 | -22.1% | 0.00% | -40.0% |
Q1 2021 | $48,121,000 | -45.3% | 2,974,087 | -10.0% | 0.01% | -44.4% |
Q4 2020 | $87,929,000 | +158.2% | 3,304,346 | +80.7% | 0.01% | +125.0% |
Q3 2020 | $34,049,000 | +95.3% | 1,828,619 | +145.4% | 0.00% | +100.0% |
Q2 2020 | $17,438,000 | – | 745,220 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bain Capital Life Sciences Investors, LLC | 8,663,673 | $40,026,000 | 4.69% |
Opaleye Management Inc. | 1,047,000 | $4,837,000 | 2.18% |
Sarissa Capital Management LP | 4,299,297 | $19,863,000 | 2.00% |
Decheng Capital Management III (Cayman), LLC | 904,268 | $4,178,000 | 1.58% |
SILVERARC CAPITAL MANAGEMENT, LLC | 850,000 | $3,927,000 | 1.21% |
Orbimed Advisors | 9,011,437 | $41,633,000 | 0.75% |
Avoro Capital Advisors LLC | 7,550,000 | $34,881,000 | 0.69% |
Rock Springs Capital Management LP | 4,075,958 | $18,831,000 | 0.55% |
Artal Group S.A. | 2,200,000 | $10,164,000 | 0.54% |
DAFNA Capital Management LLC | 406,763 | $1,879,000 | 0.51% |